Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA ... left ventricular ejection fraction, and various drugs including ACEi, ARBi, ARNI, beta-blockers, and ...

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long-acting ... which greatly influences manufacturing and drug product development. This work provides a ...

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...